Literature DB >> 2525436

The in-vitro inhibition of rat alloantigen presentation by immunotoxins--implications for allografting.

K N Wiley1, A Clark, M Fox.   

Abstract

The removal of graft interstitial dendritic cells (IDC) prior to transplantation into a recipient has been shown to improve graft survival in a number of experimental studies. We report the in-vitro properties of two immunotoxins (IT) which could be used to deplete graft IDC when administered ex vivo by hypothermic perfusion in an experimental rat transplantation model. Ricin A chain (RAC) IT targeted at either class II major histocompatibility complex (MHC) molecules or leukocyte common antigens (LCA) were prepared. These IT had similar equilibrium constants, binding kinetics and inhibiting activity of cell-free protein synthesis. IT cytotoxicity was assessed by inhibition of alloantigen presentation by targeted low density spleen cells (LDSC) in a one way mixed lymphocyte culture (MLC). When LDSC were hypothermically incubated for 2 h with IT only the anti class II MHC IT inhibited the MLC and the maximum inhibition depended on the cell allotypes. The inhibition was increased to almost 100% when chloroquine was incorporated throughout the culture period.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2525436      PMCID: PMC1541737     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Identification of Ia glycoproteins in rat thymus and purification from rat spleen.

Authors:  W R McMaster; A F Williams
Journal:  Eur J Immunol       Date:  1979-06       Impact factor: 5.532

3.  Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients.

Authors:  J R Batchelor; K I Welsh; A Maynard; H Burgos
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

4.  Renal transplantation in the inbred rat. XI. Reduction of allograft immunogenicity by cytotoxic drug pretreatment of donors.

Authors:  R D Guttmann; R R Lindquist
Journal:  Transplantation       Date:  1969-10       Impact factor: 4.939

5.  The kinetics of antibody binding to membrane antigens in solution and at the cell surface.

Authors:  D W Mason; A F Williams
Journal:  Biochem J       Date:  1980-04-01       Impact factor: 3.857

6.  Donor pretreatment as an adjunct to cadaveric renal transplantation--update 1979.

Authors:  R D Guttmann; D D Morehouse; J L Meakins; C A Milne; J Knaack
Journal:  Transplant Proc       Date:  1980-06       Impact factor: 1.066

7.  Graft adaptation: studies on possible mechanisms in long-term surviving rat renal allografts.

Authors:  D N Hart; C G Winearls; J W Fabre
Journal:  Transplantation       Date:  1980-07       Impact factor: 4.939

8.  Accessory and stimulating properties of dendritic cells and macrophages isolated from various rat tissues.

Authors:  W E Klinkert; J H LaBadie; W E Bowers
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

9.  Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells.

Authors:  R I Lechler; J R Batchelor
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

10.  Dendritic cells are the principal stimulators of the primary mixed leukocyte reaction in mice.

Authors:  R M Steinman; B Gutchinov; M D Witmer; M C Nussenzweig
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  1 in total

1.  Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells.

Authors:  Heidi A Schreiber; Jozsef Prechl; Hongquan Jiang; Alla Zozulya; Zsuzsanna Fabry; Ferencz Denes; Matyas Sandor
Journal:  J Immunol Methods       Date:  2010-02-26       Impact factor: 2.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.